Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-05
1999-12-21
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514506, 514557, 514579, 514675, 514693, 514764, 514946, A61K 31015, A61K 3112, A61K 3113, A61K 3812
Patent
active
060049278
ABSTRACT:
A method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport, the bioenhancer being present in sufficient amount to provide bioavailability of the compound in the presence of the bioenhancer greater than the bioavailability of the compound in the absence of the bioenhancer.
REFERENCES:
patent: 3862308 (1975-01-01), Schmitt et al.
patent: 4751220 (1988-06-01), Parker et al.
patent: 4822816 (1989-04-01), Markham
patent: 4849227 (1989-07-01), Cho
patent: 4944949 (1990-07-01), Story et al.
patent: 4968716 (1990-11-01), Markham
patent: 5070085 (1991-12-01), Markham
patent: 5124330 (1992-06-01), King
patent: 5156842 (1992-10-01), Mulligan
patent: 5179122 (1993-01-01), Greene et al.
patent: 5284657 (1994-02-01), Lu et al.
patent: 5288499 (1994-02-01), Janoff et al.
patent: 5332747 (1994-07-01), Van Dyke
patent: 5350756 (1994-09-01), Smith
patent: 5359030 (1994-10-01), Ekwuribe
patent: 5366980 (1994-11-01), Smith
patent: 5409690 (1995-04-01), Howell et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5422350 (1995-06-01), Woolf
patent: 5424289 (1995-06-01), Yang et al.
patent: 5436243 (1995-07-01), Sachs et al.
patent: 5455286 (1995-10-01), Amidon et al.
patent: 5466696 (1995-11-01), Woolf
patent: 5616608 (1997-04-01), Kinsella et al.
patent: 5643909 (1997-07-01), Pfister et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5652212 (1997-07-01), Cavanak et al.
Jachez, B., et al., "Restoration of Taxol Sensitivity of Multidrug-Resistant Cells by the Cyclosporine SDZ PSC 833 and the Cyclopeptide SDZ 280-446," J. Natl. Can. Inst., 85(6):478-483 (1993).
Chervinsky, D.S., et al., "Cremphor-EL Enhances Taxol Efficacy in a Multi-Drug Resistant C1300 Neuroblastoma Cell Line," Anticancer Research, 13:93-96 (1993).
Webster, L., et al., "Measurement of Cremphor EL Following Taxol: Plasma Levels Sufficient to Reverse Drug Exclusion Mediated by the Multidrug-Resistant Phenotype," J. Natl. Can. Inst., 85(20):1685-1690 (1993).
Adams, M.W., d-Alpha Tocopheryl Polyethylene glycol 1000 Succinate (Eastman vitamin E TPGS) as an Emulsifier and Bioenhancer for Drugs and Lipophilic Compounds, 6th International Conference on Pharmaceutical technology, Paris, Jun. 2-4, 1992.
Albengres et al., "Cyclosporin and Ketoconazole, Drug Interaction or Therapeutic Association?", International Journal of Clinical Pharmacology et al., 30(12): 555-570, 1992.
Akitoshi et al., Abstract "Acceleration of Transdermal Absorption of Pharmaceuticals by Essential Oils and Organic Solvents", Chem. Abst., 112:125228t, 1990.
Arias, I.M. et al., "Structure & Function of P-Glycoprotein in the Normal Liver", Xenobiotics and Cancer (L. Ernster et al., eds.), Japan Sci. Soc. Press, Tokyo/Taylor & Francis, Ltd., London, pp. 229-239, 1991.
Baciewicz et al., "Ketoconazole and Fluconazole Drug Interactions", Archives of Internal Medicine, 153(17):1970-76, 1993.
Back et al., "Comparative Effects of two Antimycotic Agents, Ketoconazole and Terbinafine on the Metabolism of Tolbutamide, Ethinyloestradiol, Cyclosporin and Ethoxycoumarin by Human Liver Microsomes In Vitro", British Journal of Clinical Pharmacology, 28:166-170, 1989.
Back et al., "Azoles, Allylamines and Drug Metabolism", British Journal of Dermatology, Supplement 39, 126:14-18, 1992.
Back, David J., and Orme, Michael L'E.; "Pharmacokinetic Drug Interactions with Oral Contraceptives", (1990) Clin. Pharmacokinet. 18(6):472-484.
Bonkovsky et al., "Cytochrome P.sub.450 of Small Intestinal Epithelial Cells", Gastroenterology, 88:458-467 (1985).
Callaghan, Richard and Riordan, John R.; "Synthetic and Natural Opiates Interact with P-glycoprotein in Multidrug-resistant Cells", (1993) J. Biol. Chem. 268(21):16059-16064.
Chan et al., "Drug Interactions with Cyclosporine: Focus on Antimicrobial Agents", Clinical Transplantation, 6:(3)(1):141-153, Jun. 1992.
Chang, Tammy et al., "The Effect of Water-Soluble Vitamin E on Cyclosporine Pharmacokinetics in healthy Volunteers", Abstract in American Society to Clinical Pharmacology and Therapeutics, 57(2):163, Feb. 1995.
Clynes, Martin; "Cellular Models for Multiple Drug Resistance in Cancer", (1993) In Vitro Cell. Dev. Biol. 29A:171-179.
de Smet et al., "Combined use of Cyclosporine and Ketoconazole in the treatment of Endogenous Uveitis", American Journal of Ophthalmology, 113:687-690, Jun. 1992.
Endicott, Jane A., and Ling, Victor; "The Biochemistry of P-glycoprotein-mediated Multidrug Resistance", (1989) Annu. Rev. Biochem. 58:137-171.
Fahr, Alfred; "Cyclosporin Clinical Pharmacokinetics" (1993) Clin. Pharmacokinetic 24(6):472-495.
Fairchild, Craig R., and Cowan, Kenneth H.; "Keynote Address: Multidrug Resistance: A Pleiotropic Response To Cytotoxic Drugs" (1991) Int. J. Radiation Oncology Biol. Phys. 20:361-367.
Fasco, Michael J. et al.; "Rat Small Intestinal Cytochromes P450 Probed by Warfarin Metabolism" (1993) Mol. Pharmacol. 43:226-233.
First et al., "Concomitant Administration of Cyclosporin and Ketoconazole in Renal Transplant Recipients", The Lancet, 2:1198-1201, Nov. 18, 1989.
First et al., "Cyclosporine Dose Reduction by Ketoconazole Administration in Renal Transplant Recipients", Transplantation, 51(2):365-370, Feb. 1991.
Fojo, Antonio T.; "Multidrug Resistance" (1991) Adv. Intern. Med. 36:195-218.
Gatmaitan, Zenaida C. and Irwin M. Arias; "Structure and Function of P-Glycoprotein in Normal Liver and Small Intestine" (1993) Adv. Pharmacol. 24:77-97.
Greenblatt. David J.; "Presystemic Extraction: Mechanisms and Consequences" (1993) J. Clin. Pharmacol 33:650-656.
Hait, William N. et al.; "Terfenadine (Seldane.RTM.):A New Drug for Restoring Sensitivity to Multidrug Resistant Cancer Cells" (1993) Biochem. Pharmacol 45:401-406.
Hebert, Mary F. et al.; "Bioavailability of Cyclosporine with Concomitant Rifampin Administration is Markedly Less Than Predicted by Hepatic Enzyme Induction" (1992) Clin. Pharmacol. Ther. 52:453-457.
Henricsson et al., "Cyclosporin Metabolism in Human Liver Microsomes and its Inhibition by Other Drugs", Pharmacology & Toxicology, 66:49-52, 1990.
Hsing, Shu et al.; "The Function of Gp170, the Multidrug-Resistance Gene Product. in the Brush Border of Rat Intestinal Mucosa" (1992) Gastroenterology 102:879-885.
Hunter, J. et al., "Epithelial Secretion of Vinblastine by Human Intestinal Adenocarcinoma Cell (HCT-8 and T84) Layers Expressing P-Glycoprotein", British Journal of Cancer, 64:437-444, 1991.
Hunter, Janice et al.; "Functional Expression of P-glycoprotein in Apical Membranes of Human Intestinal Caco-2 Cells" (1993) J. Biol. Chem. 268:14991-14997.
Jancis, Erik M. et al.; "Estradiol Induction of Rhodamine 123 Efflux and the Multidrug Resistance Pump in Rat Pituitary Tumor Cells" (1993) Mol. Pharmacol. 43:51-56.
Kaminsky, Laurence, and Michael J Fasco; "Small Intestinal Cytochromes P450" (1992) Toxicology 21(6):407-422.
Kolars, Joseph C. et al.; "Identification of Rifampin-inducible P450IIIA4 (CYP3A4) in Human Small Bowel Enterocytes" (1992) J. Clin. Invest. 90:1871-1878.
Kolars, Joseph C. et al.; "Heterogeneity of Cytochrome P450IIIA Expression in Rat Gut Epithelia" (1992) Gastroenterology 102:1186-1198.
Kolars, Joseph C. et al.; "Cyclosporine Metabolism by P450IIIA in Rat Enterocytes--Another Determinant of Oral Bioavailability?" (1992) Transplantation 53:596-602.
Komori, Masayuki et al.; "Cytochrome P-450 in Human Liver Microsomes: High-Performance Liquid Chromatographic Isolation of Three Forms and Their Characterization" (1988) J. Biochem. 104:912-916.
Kralovanszky, et al.; "Isolation of Viable Intestinal Epithelial Cells and Their Use for in Vitro Toxicity Studies", In Vivo 4:201-204, 1990.
Kronbach, Thomas et al.; "Cyclosporine Metabolism in Human Liver: Identification of a Cytochrome P450III Gene Family as the Major Cyclosporine Metabolizing Enzyme Explains Interactions of Cyclosporine With
Benet Leslie
Wu Chi Yuan
Regents of the University of California
Russel Jeffrey E.
LandOfFree
Method for increasing bioavailability of orally administered pha does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing bioavailability of orally administered pha, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing bioavailability of orally administered pha will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-505082